Early pharmacological prophylaxis has been reported to increase the return of spontaneous erections following radical prostatectomy (RP). In this study, we evaluated the role of intracavernosal alprostadil (PGE1) combined with sildenafil in stimulating early recovery of spontaneous erections following RP. In this prospective study, we included 22 patients who underwent bilateral nerve-sparing RP after October 2004. Sildenafil dose of 50 mg/day was started at the time of hospital discharge. Of 22 patients, 18 started on PGE1-4 lg (1-8) and four started on low-dose Trimix (20 U) 2-3 times/week. These patients are followed up at regular intervals (3, 6, 9 and 12 months) with abridged version of the International Index for Erectile Function-5 questionnaire. Patient compliance, return of sexual activity and return of natural erection, adverse effects and reasons for discontinuation were recorded. Penile doppler studies were performed during followup visits to assess the vascular status. After a mean followup of 6 months (3-8 months), 11/22 (50%) patients had return of spontaneous partial erections. Of the 18 PGE1 users, six continued 4 lg PGE1, four increased the dose to 8 lg, six decreased the dose to 2 lg and two patients further reduced the dose to 1 lg. Of four low-dose Trimix users, three increased the dose to 30 U and one reduced the dose to 15 U. Of 22 patients, 21 were sexually active: 12/21 (57%) with the injections alone and 9/21 (42.9%) with combination therapy (injections (PGE1) and sildenafil). Penile doppler studies revealed arterial insufficiency in 77% (17/22) patients and venous insufficiency in one patient. Early intracavernosal injections following RP facilitated early sexual intercourse, patient satisfaction and potentially earlier return of natural erections. Early combination therapy with sildenafil allowed a lower dose of intracavernous injections, minimizing the penile discomfort.
Introduction
Erectile dysfunction (ED) is a common long-term complication following radical prostatectomy (RP). 1 The potency rates following RP range from 16 to 86% and the time period for the recovery varies from 6 to 24 months. 2, 3 Erectile dysfunction rates remain high even after nerve-sparing surgery in the hands of experienced surgeons. This reality has forced many urologists to formulate alternative strategies to promote recovery of erectile function. The recent advances in the understanding of penile hemodynamics have further encouraged physicians to develop early penile rehabilitation programs to promote nerve recovery and to prevent cavernosal hypoxia.
The pathophysiology of ED following RP is multifactorial. Neurogenic and vasculogenic factors have been the principal focus. A temporary period of neuropraxia is inevitable, despite technically excellent nerve-sparing surgery. 2, 4 During this period of neuropraxia, absence of spontaneous erections predispose to cavernosal hypoxia. Persistent cavernosal hypoxia induces cavernosal fibrosis due to accumulation of collagen. 5 Cavernosal fibrosis produced over time due to persistent penile hypoxia has been shown to increase the incidence of venoocclusive dysfunction. 6 Recently, there has been great enthusiasm in early interventions to prevent penile hypoxia and its longterm complications. Montorsi et al., 7 first demonstrated the advantage of early rehabilitation in patients after bilateral nerve-sparing RP by using intracavernosal alprostadil (PGE1). This study generated a great deal of interest and enthusiasm in the field of early penile rehabilitation. However, no further confirmatory studies have been reported since 1997. This may be due to the lack of compliance with injections, since small doses of PGE1 can cause significant penile discomfort.
Recently, in an effort to further study the role of early interventions at the same time to improve the patient compliance, oral agents were used. 8 PadmaNathan et al. 9 first evaluated the role of sildenafil in potency preservation. In this series, 27% of patients using early daily sildenafil reported return of natural erections compared to 4% in control group. However, 73% of patients were sexually inactive at the end of 1 year. In an effort to improve sexual activity, we felt combination therapy with intracavernosal injections and oral sildenafil was the best approach. The patient would receive daily vasodilatation from sildenafil and could remain sexually active with injections. The injections would also provide a much stronger stimulus to the penile vasculature (improving arterial insufficiency) and could potentially decrease the degree of venous leakage. 7 This study was designed to evaluate the role of combination therapy-intracavernosal injections and sildenafil in early return of sexual activity and the early recovery of natural erections following nervesparing RP.
Materials and methods
In this prospective study, we included 22 consecutive preoperative sexually active patients who underwent bilateral nerve-sparing RP after October 2004. All patients were operated by a single surgeon (CZ). The Cleveland Clinic Institutional Review Board approved this study and all patients granted their written informed consent. All eligible patients were initially evaluated with a comprehensive sexual history, physical examination, and pertinent laboratory testing. The mean age was 58.376.9 years and mean prostate-specific antigen was 8.773.9 (Table 1) . None of the patients who participated in the study received either neoadjuvant or adjuvant hormonal treatment or adjuvant radiation.
Preoperative assessment
Patients who participated in this study were initially evaluated by the Sexual Health Inventory for Men (SHIM) questionnaire as a baseline. Comorbid conditions like diabetes, hypertension, hyperlipidemias and cardiac diseases were noted. Of the 22 patients, two patients had long-term diabetes controlled on oral hypoglycemics, one patient had history of hypertension on life style modification. None of the study population had any cardiac diseases.
Postoperative treatment
Sildenafil citrate at a dose of 50 mg once daily was started at the time of hospital discharge. Patients having headaches are advised to reduce the dose to 25 mg. Initial injection training was performed in the office by an experienced assistant either at the time of catheter removal or within 3 weeks after catheter removal. The initial injection consisted of either alprostadil (PGE1-4 mg) or low-dose Trimix (20 U). Low-dose Trimix is a mixture of prostaglandin E1 (5.88 mg/ml), papavarine (17.65 mg/ml) and phentolamine (0.59 mg/ml) -1 ml ¼ 100 U (This mixture is purchased from the Hospital pharmacy). Penile doppler study was performed at the time of the initial injection. Dose adjustments were made according to the pain and response with the injection. If there is penile pain during the first injection, dose of injection is reduced. Patient education regarding the safety profile of injections and precautions were explained during this visit. Patients were advised to do injections 2-3 times/ week until natural erections occurred.
Follow-up and dose modifications
Further dose adjustments were done according to the patient's desire and side effects to obtain maximum compliance with the injection program. The dose of PGE1 was reduced if patients had penile pain. Patients were followed up at regular intervals (3, 6, 9 and 12 months). At each visit data were obtained on injection dose, sexual activity, International Index of Erectile Function-5 (IIEF-5) score (with sildenafil alone, injections alone and natural erections), side effect profile and rigidity. Penile doppler studies were performed at 3-and 6-month Early combination therapy K Nandipati et al visits to assess the blood flow and any development of venous leak.
Survey and data assessment
The patients' response to injections was assessed using the SHIM questionnaire, which is an abridged IIEF-5 questionnaire. 9 International Index for Erectile Function-5 is a validated, multidimensional, self-administered questionnaire that is a sensitive indicator of changes in erectile function. 10, 11 The SHIM was scored from 1 to 5, with the scores indicating the following: 1 ¼ never or occasionally; 2 ¼ less than half the time; 3 ¼ sometimes/half of the time; 4 ¼ more than half of the time and 5 ¼ almost always. The combined SHIM scores were calculated by totaling the response to all five questions. Baseline SHIM scores were compared to scores obtained after treatment with combination treatment to determine the change in response. The return of natural erections and erections sufficient for vaginal intercourse, SHIM of natural erections and reasons for treatment discontinuation were also assessed.
Penile doppler was performed using an UroMetrics Knoll/MIDUS Ultrasound with an 8-MHz linear transducer (Urometrics, Inc., MN, USA). The doppler was performed after dose optimization and re-injections if necessary. Rigid erection lasting for at least 30 min was considered as optimum erection. Prostaglandin 8-10 mg or low-dose trimix 20 U was used for initial Doppler. If the patient had suboptimal response with this dose, the dose was increased in the next Doppler sitting. Hemodynamic data were collected at 5, 10 and 20 min, and the best peak systolic velocity (PSV), end diastolic velocity (EDV) and the resistance index (RI) were calculated. The normal doppler values are PSV 430 cm/s, EDV o5 cm/s and RI 0.70. Peak systolic velocity o30 cm/ s is considered as arterial insufficiency and EDV 45 cm/s is defined as veno-occlusive dysfunction (venous leak). When both PSV and EDV are abnormal, it is considered as mixed vasculogenic insufficiency. 6, 12 Statistical analysis The data represented as mean7standard deviation (s.d.). The comparison of SHIM with the baseline and after use of injections or combination therapy was performed using Wilcoxon test. The return of any natural erections and return of erection sufficient for vaginal intercourse, quality of erections and reason for discontinuation were also assessed. The influence of patient age on return of natural erections was assessed. Study population was divided into two groups (460 years, o60 years) and comparison between both groups was carried out with Fisher's test. The numbers of patients discontinuing treatment for multiple reasons were calculated as a percentage of the total. Doppler results were represented as mean7s.e.m. Statistical significance was assessed with a two-tailed test at Po0.05. Computations utilized SAS version 8.1 software (SAS Institute, Inc., Cary, NC, USA).
Results
With a mean followup of 6 (3-8) months, 21/22 (96%) patients were sexually active. The single sexually inactive patient achieved sufficient erection for intercourse, but was reluctant to have sexual activity due to urinary incontinence. Of 18 patients using PGE1, eight (45%) are sexually active with injections alone and nine (50%) were sexually active with combination of sildenafil ( Table 2) . Of the four low-dose Trimix users, all were sexually active with injections alone. The mean IIEF-5 scores in the injections alone group and combination treatment group were significantly higher compared to the postoperative baseline (without any erectaids) following surgery (Table 3 ) (Po0.05). However, the mean IIEF-5 with the sildenafil alone was not significantly higher than postoperative baseline (P40.05) ( Table 4) .
Eleven of 22 (50%) of patients reported the return of spontaneous partial erections. However, none of these patients reported erections sufficient for Table 3) . While analyzing the influence of age on return of natural erections, we found that patients p60 years had a higher incidence of return of natural erections (9/12, 75%) compared to the patients 460 years (2/10, 20%) of age (P ¼ 0.03). Of 18 PGE1 users, six continued 4 mg of PGE1, four increased the dose to 8 mg due to inadequate response, six decreased the dose to 2 mg and two patients further reduced the dose to 1 mg due to pain and discomfort (Table 2) . Of four patients started on low-dose Trimix (20 U), one reduced the dose to 15 U because of prolonged erections (2 h) and three increased the dose to 30 U because of inadequate response. Penile discomfort was noticed in two patients using 8 mg of PGE1. Two patients using sildenafil noticed transient headaches. However, none of the patients discontinued the treatment.
The penile doppler studies using compliant injection doses (pain free) revealed normal blood flow (PSV 430 cm/s, EDV o5 cm/s) in 4/22 (18%) patients, mild arterial insufficiency (PSV o30 cm/s) in 17/22 (77%) patients and venous leak in 1/22 (5%) patients 6 months after surgery. The PSV and EDV (mean7s.e.m.) in the right cavernosal artery were 24.571.5 cm/s (range 14-34) and 2.471.5 cm/s (0-8).
The PSV and EDV in the left cavernosal artery were 27.8710.5 cm/s (range 17-60) and 2.371.5 cm/s (0-8). When comparing the compliant doses of injections, the mean PSVs were higher in low-dose Trimix users (29.872.9 cm/s; 17-60) compared to the low-dose PGE1 alone (19.773.2 cm/s; 14-34). These results suggest that low-dose Trimix provides stronger stimuli to the penile vasculature than low-dose PGE1.
Comment
Erectile dysfunction is a common complication following nerve-sparing RP. The recovery of erectile function may take up to 18-24 months. 13, 14 The lack of spontaneous erections during the period of neuropraxia has been implicated to produce persistent penile hypoxia. The hypoxia and a consistently flaccid penis are etiological factors for fibrosis. Clinically, penile fibrosis is manifested as a progressive decrease in the penile girth and length following RP. 15 On a molecular level, this has been reported in animal studies as an increased expression of TGF-b 1 and collagen. 16 Recently, Iacono et al. 5 reported that there is a significant increase in collagen content in human penile biopsies after RP. The concept of early penile rehabilitation is introduced to interrupt this cascade of events.
There is a paucity of reports describing the effects of early penile rehabilitation on ED following RP. The first landmark study by Montorsi et al. 7 in 1997 reported that early PGE1 significantly improved the return of natural erections compared to the observational group (67 vs 20%). However, the number of subjects in this report was limited, with only 12 patients completing the early treatment arm. Interestingly, in these patients using the early treatment arm 83% had normal venous doppler (EDV 45 cm/ s) compared to the 47% in the observational group. More recently, using oral therapy, Padma-Nathan et al. 9 reported that early daily use of sildenafil citrate significantly increased the return of natural erections compared to the controls (27 vs 4%). The Early combination therapy K Nandipati et al results of these two studies prompted us to do an early combination program consisting of daily sildenafil and low-dose intracavernosal injections. Our results at 6 months showed a return of spontaneous erections in 50% of patients, incidence comparable to Montorsi's 6 months data. Our study provides the first confirmation of Montorsi's early results that early penile injections can favorably influence the return of natural erections. Alprostadil is one of the most powerful vasoactive agents currently available for the diagnosis and treatment of ED. 16 Intracavernous alprostadil is a synthetic prostaglandin derivative used in the treatment of ED. The effect of PGE1 in return of natural erections was initially reported by Montorsi et al. in 1997. They hypothesized that early intracavernous alprostadil prevents the cavernosal hypoxia and increases the return of natural erections. In his series, the mean dose of 8 mg (2.5-14 mg) was used to achieve rigid and sustained erections. However, the anecdotal experience of many investigators was that this mean dose causes considerable pain and lack of compliance. Only 4/18 (22%) patients using PGE1 could tolerate the 8 mg dose, with the majority of patients using 2-4 mg. None of the patients using low-dose Trimix (15-30 U) reported any pain. These dose modifications according to the pain allowed 100% compliance in our study.
Sildenafil citrate is a commonly used oral treatment option for ED. There is a growing interest recently to use once daily phosphodiesterase-5 inhibitors to prevent cavernosal hypoxia. The role of sildenafil in preservation of smooth muscle content was reported by Schwarz et al. 8 in human penile biopsy studies. They reported this at 6 months. Daily sildenafil at 50 mg was shown to preserve the smooth muscle content, and at a higher dose of 100 mg the smooth muscle content is significantly increased over the baseline. Clinically, PadmaNathan et al. 9 reported that, after 11 months followup, 14 of 51 (27%) patients receiving daily sildenafil had return of natural erections sufficient for intercourse compared to 1/25 (4%) in the placebo group. This study revealed that oral daily sildenafil increased the return of erections sevenfold compared with the placebo group, and was well tolerated. However, the major disadvantage with oral sildenafil alone is that vast majority of the study population were sexually inactive or unable to achieve vaginal intercourse. Early use of injections (with or without sildenafil) in our study allowed a vast majority (96%) to be sexually active and improve patient satisfaction. It is unclear from our study whether early sildenafil has increased the incidence of return of natural erections. However, this combination treatment allowed us to reduce the dose of intracavernosal injections.
In evaluating our early rehabilitation therapy, we felt it is important to carry out chronologic penile doppler studies following surgery to monitor and assess our results. The available physiologic literature would indicate that the degree of postoperative arterial insufficiency influences the closure of the subtunical space and influences the degree of venoocclusive disease (venous leak). It has been hypothesized and potentially confirmed by Montorsi et al. with his small series that early injections could improve the arterial insufficiency and decrease the incidence of venous leak.
In 1996, with a small series of patients, Mulhall and Graydon 17 first reported that all patients (n ¼ 10) with ED following RP had significant arteriogenic insufficiency and 60% had venous leakage at 6 months. In a followup study, with a larger study population Mulhall et al. reported that on chronological followup the arterial insufficiency remained at approximately 60%, but the incidence of venous leak increased considerably (14% at 4 months, 21% between 4 and 8 months, and 50% after 12 months). The implication of this study is that persistent arterial insufficiency may cause corporal fibrosis and is conducive to progressive veno-occlusive dysfunction. 18 In reporting penile doppler at 6 months, Montorsi et al. 7 showed that the incidence of veno-occlusive dysfunction was significantly higher in the observation group (no injections) compared to the early treatment group (PGE1) (53 vs 17%). These results are compared favorably with our early results, with only 1/22 (5%) demonstrating a venous leak at 6 months. Compared to the contemporary controls in the Mulhall et al. 6 study, the lack of linear increase in the incidence of venous leak in our study may be due to the early initiation of intracavernosal injections. The mild arterial insufficiency is seen in 77% of patients and it remained stable at 3 and 6 months, results similar to that reported in the Mulhall et al. study.
Certain caveats are noteworthy in our study. This is a nonrandomized prospective study with no contemporary control group. As the mean age of our surgical population decreased considerably, randomization to a no treatment group is becoming increasingly difficult. Most of our younger patients are very interested in early rehabilitation programs and wanted to be sexually active after surgery. Early rehabilitation may never be shown to improve conclusively the incidence of sexual intercourse, but it might definitely improve sexual activity and return of spontaneous natural erections. Thus, the available research clinical data would suggest that early rehabilitation causes no harm.
Conclusion
Erectile dysfunction following RP is underdiagnosed, underreported and undertreated. The technical improvements in open surgical technique have provided modest, if any, improvement in results.
Early combination therapy K Nandipati et al Thus, the emphasis needs to be shifted to early rehabilitation. Early penile rehabilitation can hopefully shorten the period of neuropraxia and improve the return of natural erections. Our early results with combination therapy using daily sildenafil and intracavernosal injections confirm the landmark study by Montorsi et al. in 1997 that early treatment can improve the return of natural erections and improve penile hemodynamics. The additional benefit with the daily sildenafil is unclear, but daily mild vasodilatation is probably beneficial, as shown by Padma-Nathan et al., and has a high degree of patient compliance. Given the unknown nature of the pathophysiology of erectile recovery, it seems to be prudent to maximally vasodilate with more than one therapy to augment penile hemodynamics. Early injections facilitate early sexual intercourse, patient satisfaction and potentially early return of spontaneous erections. Combination therapy with sildenafil allows lower dose of intracavernous injections, which decreases the discomfort. Whether, the earlier return of natural erections at 6 months translates into a higher incidence of sexual intercourse at 12-18 months remains to be seen. Our 50% incidence of spontaneous erections at 6 months has not been seen in any of our contemporary controls, thus causing optimism that the hypothesis that 'early is better' remains true.
